Dr. Andrew Loblaw named Fellow of American Society of Clinical Oncology

Congratulations to Sunnybrook radiation oncologist Dr. Andrew Loblaw, who has been named a Fellow of the American Society of Clinical Oncology (ASCO).

This distinction recognizes ASCO members for their extraordinary volunteer service, dedication, and commitment to ASCO. Their efforts benefit ASCO, the specialty of oncology, and, most importantly, the patients at risk for or with cancer.

Dr. Loblaw is a radiation oncologist, clinician scientist and an associate professor in the departments of radiation oncology and health policy management and evaluation at the University of Toronto. He has a masters in clinical epidemiology from the University of Toronto, and is a graduate of the Royal College's Clinician Investigator Program. His clinical practice focuses on prostate cancer and the healthcare system as a whole.

His ASCO work has focused on the development and dissemination of clinical practice guidelines, which are the keystone to evidence-based, high-quality care. He is past-chair of the Genitourinary Guideline Advisory Group at ASCO and has chaired several guideline committees in the management of prostate cancer. These guidelines have been cited in over 1,500 articles. He continues to co-chair of the program in evidence-based care genitourinary group at CCO.

Dr. Loblaw’s pioneering research has greatly improved the outcomes for Sunnybrook’s cancer patients and beyond. His work has shown that five treatments of Stereotactic Ablative Body Radiotherapy (SABR) is more effective than 38 treatments of external beam radiation for favorable risk prostate cancer patients. He has also helped pioneer a new internal radiation treatment (brachytherapy) that also holds the same promise as SABR. His research and guideline leadership has led to a change in the standard of care in a number of areas including brachytherapy, SABR, hormone-sensitive prostate cancer, castrate-resistant prostate cancer and malignant spinal cord compression.

Please join us in congratulating Dr. Loblaw on this honour.